HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

USP Ephedra Review Scheduled For July; RAND Report Slated For Early Fall

This article was originally published in The Tan Sheet

Executive Summary

The U.S. Pharmacopeia will discuss standard-setting issues related to the supplement ingredient ephedra during an internal meeting July 17

You may also be interested in...



Metabolife Federal Probe Spurs Release Of Ephedrine Complaint Records

An FDA task force will review the 13,000 ephedrine alkaloid patient complaint records Metabolife is releasing in response to publicity surrounding a criminal investigation into whether the company lied about its knowledge of adverse events

NTP Ephedrine Alkaloid Toxicity Studies Under Review

The National Toxicology Program is asking for toxicology data on ephedrine alkaloid dietary supplements by Aug. 12

Saw Palmetto "Moderate" Quality Evidence Shows BPH Symptom Relief - USP

The U.S. Pharmacopeia's final monograph on saw palmetto lists 10 published studies on the ingredient that met the USP quality standard of Level II or higher, under the organization's new criteria for evidence submission for botanicals.

Related Content

Topics

UsernamePublicRestriction

Register

OM006664

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel